We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Chugai, a mid-ranked Japanese drug producer, has reported encouraging interim
results of JPY34.1bn (US$331.21mn) for 2004, about 8% higher than its own forecast.
According to local sources, Japanese drug major Takeda plans to increase its
US sales presence, increasing its medical representatives to roughly 4,000.
Following December's accusations in the international press that German drug
major Boehringer-Ingelheim distorted study results on its Viramune (Nevirapine)
HIV/AIDS treatment, controversy over the drug continues to grow.
Canada's Lorus Therapeutics, a biopharmaceutical firm specialising
in cancer treatments, has reported a slight lower year-on-year improvement in
losses in the three months ended November 30, totalling some CAD5.9mn (US$4.84mn).
Following reforms already enacted to Germany's insurance-based reimbursement
system, health funds have announced new pricing discussions with the drug industry,
which are expected to affect margins.
US studies comparing AstraZeneca's Symbicort asthma treatment with alternatives
have reported favourable results for the UK- and Sweden-based drug major.